| Mr John Patrick Shalhoub, LCSW | |
|
500 N Bridge St, Bridgewater, NJ 08807-2135 | |
| (908) 725-2800 | |
| (908) 704-1790 |
| Full Name | Mr John Patrick Shalhoub |
|---|---|
| Gender | Male |
| Speciality | Clinical Social Worker |
| Experience | 25 Years |
| Location | 500 N Bridge St, Bridgewater, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093880734 | NPI | - | NPPES |
| 527486 | Other | NJ | AGENCY MEDICARE PROIVDER NUMBER |
| 0023701 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 44SC05183500 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northstar Counseling Services Llc | 6204144165 | 6 |
News Archive
Liver disease death rates are rising in the UK, in contrast to other common diseases such as heart disease and cancer, and the new Robert Hesketh Hepatology Clinical Research Facility aims to provide care and develop new therapies to reverse this trend.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.
Researchers from CIC bioGUNE's Structural Biology Unit and Columbia University (New York) have conducted a joint research project, published in the prestigious scientific journal Structure, to gain in-depth knowledge of the structure of pyruvate carboxylase when it is in solution (in the "natural" state).
Investigators at The Research Institute at Nationwide Children's Hospital are studying a potential new treatment strategy for dominant forms of muscular dystrophy, thanks to preliminary funding from The Ohio State University Center for Clinical and Translational Science.
Perrigo Company plc today announced that it has received final approval from the U.S. Food & Drug Administration for its abbreviated new drug application for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets (repaglinide tablets) and has commenced shipment of product. Perrigo previously launched the 0.5 mg strength in 2013.
› Verified 4 days ago
| Entity Name | St Lukes Warren Physician Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467725184 PECOS PAC ID: 9739093675 Enrollment ID: O20031117000020 |
News Archive
Liver disease death rates are rising in the UK, in contrast to other common diseases such as heart disease and cancer, and the new Robert Hesketh Hepatology Clinical Research Facility aims to provide care and develop new therapies to reverse this trend.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.
Researchers from CIC bioGUNE's Structural Biology Unit and Columbia University (New York) have conducted a joint research project, published in the prestigious scientific journal Structure, to gain in-depth knowledge of the structure of pyruvate carboxylase when it is in solution (in the "natural" state).
Investigators at The Research Institute at Nationwide Children's Hospital are studying a potential new treatment strategy for dominant forms of muscular dystrophy, thanks to preliminary funding from The Ohio State University Center for Clinical and Translational Science.
Perrigo Company plc today announced that it has received final approval from the U.S. Food & Drug Administration for its abbreviated new drug application for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets (repaglinide tablets) and has commenced shipment of product. Perrigo previously launched the 0.5 mg strength in 2013.
› Verified 4 days ago
| Entity Name | Northstar Counseling Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871977702 PECOS PAC ID: 6204144165 Enrollment ID: O20150928000444 |
News Archive
Liver disease death rates are rising in the UK, in contrast to other common diseases such as heart disease and cancer, and the new Robert Hesketh Hepatology Clinical Research Facility aims to provide care and develop new therapies to reverse this trend.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.
Researchers from CIC bioGUNE's Structural Biology Unit and Columbia University (New York) have conducted a joint research project, published in the prestigious scientific journal Structure, to gain in-depth knowledge of the structure of pyruvate carboxylase when it is in solution (in the "natural" state).
Investigators at The Research Institute at Nationwide Children's Hospital are studying a potential new treatment strategy for dominant forms of muscular dystrophy, thanks to preliminary funding from The Ohio State University Center for Clinical and Translational Science.
Perrigo Company plc today announced that it has received final approval from the U.S. Food & Drug Administration for its abbreviated new drug application for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets (repaglinide tablets) and has commenced shipment of product. Perrigo previously launched the 0.5 mg strength in 2013.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr John Patrick Shalhoub, LCSW 500 N Bridge St, Bridgewater, NJ 08807-2135 Ph: (908) 725-2800 | Mr John Patrick Shalhoub, LCSW 500 N Bridge St, Bridgewater, NJ 08807-2135 Ph: (908) 725-2800 |
News Archive
Liver disease death rates are rising in the UK, in contrast to other common diseases such as heart disease and cancer, and the new Robert Hesketh Hepatology Clinical Research Facility aims to provide care and develop new therapies to reverse this trend.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.
Researchers from CIC bioGUNE's Structural Biology Unit and Columbia University (New York) have conducted a joint research project, published in the prestigious scientific journal Structure, to gain in-depth knowledge of the structure of pyruvate carboxylase when it is in solution (in the "natural" state).
Investigators at The Research Institute at Nationwide Children's Hospital are studying a potential new treatment strategy for dominant forms of muscular dystrophy, thanks to preliminary funding from The Ohio State University Center for Clinical and Translational Science.
Perrigo Company plc today announced that it has received final approval from the U.S. Food & Drug Administration for its abbreviated new drug application for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets (repaglinide tablets) and has commenced shipment of product. Perrigo previously launched the 0.5 mg strength in 2013.
› Verified 4 days ago
Amy B. Acker, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 672 Us Highway 202/206, Building 3, Suite 106, Bridgewater, NJ 08807 Phone: 973-769-2401 | |
Vilma Ramirez, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 500 N Bridge St, Bridgewater, NJ 08807 Phone: 908-725-2800 Fax: 908-704-1790 | |
Mrs. Susan Darien, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 16 Gateshead Drive, Bridgewater, NJ 08807 Phone: 908-704-1001 Fax: 908-252-9808 | |
Jay Weintraub, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 500 N Bridge St, Bridgewater, NJ 08807 Phone: 908-725-2800 Fax: 908-704-1790 | |
Margo Lee Tarasov, SW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: Rr 22 West, Bridgewater, NJ 07920 Phone: 908-202-4801 | |
Camille Feola, MSW, LSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 500 N Bridge St, Bridgewater, NJ 08807 Phone: 732-725-2800 Fax: 908-704-1790 | |
Marilyn Mccusker, LCADC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 540 Route 22, Bridgewater, NJ 08807 Phone: 908-722-1881 |